Amgen's decision reverberated beyond the 48 patients in the trials because the drug, called glial cell line-derived neurotrophic factor, or GDNF, had the potential to stall or even reverse the progression of the disease rather than just reduce the symptoms, as the currently available Parkinson's drugs do.
The company said it would not make the drug available to the 48 patients who had participated in its clinical trials, even though the Food and Drug Administration had left the door open for it to do so.
Two months later, the company said that safety issues had been discovered and it abruptly
